发明名称 |
Imidazo bicyclic iminium compounds as antitumor agents |
摘要 |
Compounds of formula I:;
are disclosed. The compounds are inhibitors of Hedgehog pathway activation and are useful in treating solid tumors. An example of such a compound is:
; |
申请公布号 |
US9611276(B2) |
申请公布日期 |
2017.04.04 |
申请号 |
US201314409683 |
申请日期 |
2013.06.19 |
申请人 |
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
发明人 |
Chen James;Kato Tomoyo Sakata;Ondrus Alison Evelynn |
分类号 |
C07D515/04;C07D513/04;A61K31/437;C07D471/04;C07D487/04;A61K31/4188;A61K31/429;A61K31/5383;A61K31/55;C07D498/04 |
主分类号 |
C07D515/04 |
代理机构 |
Heslin Rothenberg Farley & Mesiti, P.C. |
代理人 |
Heslin Rothenberg Farley & Mesiti, P.C. ;Hansen Philip |
主权项 |
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula II: wherein: R1 is chosen from optionally substituted aryl and optionally substituted heteroaryl; R2a is chosen from H and (C1-C4)alkyl; R3a is chosen from optionally substituted aryl and optionally substituted heteroaryl; A1 is (a) a fused, saturated ring of 7 members that contains no heteroatoms other than the nitrogen at the point of fusion, said saturated ring optionally substituted with one or two (C1-C4)alkyl residues or
(b) a fused bicycle, one ring of said fused bicycle being a saturated ring of 7 members that contains no heteroatoms other than the nitrogen at the point of fusion and a second ring of said fused bicycle being a benzene ring, said bicycle optionally substituted with one or two (C1-C4)alkyl residues; and X is any counterion. |
地址 |
Stanford CA US |